DEFA14A: Aadi Bioscience to Sell FYARRO, In-License ADC Portfolio, and Secure $100 Million PIPE Financing

Aadi Bioscience is urging stockholders to vote in favor of proposals to sell FYARRO, in-license antibody drug conjugates (ADCs), and secure a $100 million private investment to transform the company and maximize shareholder value.

Summary

• Aadi Bioscience is seeking stockholder approval for a series of strategic transactions.
• These transactions include the sale of FYARRO and its associated infrastructure to Kaken Pharmaceuticals for $100 million in cash.
• Aadi plans to in-license a portfolio of antibody drug conjugates (ADCs) from WuXi Biologics.
• The company also aims to secure a $100 million private investment in public equity (PIPE) financing.
• The company believes these moves will position Aadi to develop next-generation oncology therapies.
• The company believes it will create long-term value for stockholders.
• Upon announcement of these transactions in December 2024, Aadi's stock price rose 46% in the first day of trading.
• The Special Meeting of Stockholders is scheduled to be held on February 28, 2025.

Sentiment

Score: 7

Explanation: The document conveys a positive outlook due to the strategic transactions aimed at transforming the company and maximizing shareholder value. The stock price increase upon announcement further supports this sentiment, although risks associated with the transactions and product development temper the overall optimism.

Positives

• The sale of FYARRO provides Aadi with $100 million in cash.
• In-licensing ADCs expands Aadi's pipeline with promising cancer treatments.
• The $100 million PIPE financing will enable the development of these new assets.
• The company's stock price reacted positively to the announcement of these transactions.
• The company believes it will have an enhanced pipeline of leading ADC assets and the capital it needs to unlock the potential of our portfolio.

Negatives

• The company is selling its existing product, FYARRO.
• The transactions are subject to stockholder approval, which is not guaranteed.
• The company is reliant on the successful development and commercialization of in-licensed ADC assets.

Risks

• The closing of the proposed sale of FYARRO or the PIPE financing may not occur if conditions are not satisfied, including failure to obtain stockholder approval.
• There are uncertainties regarding the timing of the consummation of the proposed transactions.
• Aadi may face challenges in managing its operating expenses and expenses associated with the proposed transactions pending the closing.
• Required approvals from governmental or quasi-governmental entities may not be obtained in a timely manner or at all.
• Unexpected costs, charges, or expenses may result from the transactions.
• Potential adverse reactions or changes to business relationships may occur following the announcement or completion of the proposed sale of FYARRO or the proposed PIPE financing.
• There are uncertainties associated with Aadi's product candidates, including potential delays in preclinical studies and clinical trials.
• Aadi may be unable to obtain sufficient additional capital to continue to advance these product candidates.
• Obtaining successful preclinical and clinical results for product candidates is uncertain, and unexpected costs may result.
• There is a risk of failing to realize any value from product candidates being developed.
• The anticipated benefits of the proposed sale of FYARRO or the proposed PIPE financing may not be realized.

Future Outlook

Aadi believes that upon closing these three strategic transactions, it will be well positioned to develop next-generation oncology therapies and create long-term value for stockholders, with an enhanced pipeline of leading ADC assets and the capital needed to unlock the potential of its portfolio.

Management Comments

• David Lennon, Ph.D., President & Chief Executive Officer, encourages stockholders to vote in favor of the proposals.
• The Board concluded the best path forward for Aadi involves the sale of FYARRO, in-licensing of ADCs, and a PIPE financing.
• The Board strongly recommends this series of transactions as the best way to transform Aadi and maximize value for its shareholders.

Industry Context

Aadi's move to in-license ADC assets reflects a growing trend in the oncology space, with many companies focusing on targeted therapies. The sale of an existing asset to fund the development of new ones is a common strategy in the biotech industry.

Comparison to Industry Standards

• Many biotech companies, such as Seagen and ImmunoGen, are heavily invested in ADC technology, indicating its potential in cancer treatment.
• PIPE financings are a common method for publicly traded biotech companies to raise capital, with similar deals seen at companies like BioNTech and Moderna.
• Selling existing assets to focus on core competencies or fund new developments is a strategy employed by companies like Novartis and Roche.

Stakeholder Impact

• Shareholders are expected to benefit from the potential long-term value creation through the development of new oncology therapies.
• Employees associated with FYARRO may be affected by the sale to Kaken Pharmaceuticals.
• The company's strategic shift may impact its relationships with suppliers and partners.

Next Steps

• Stockholder vote on the proposed transactions at the Special Meeting on February 28, 2025.
• Closing of the sale of FYARRO to Kaken Pharmaceuticals.
• In-licensing of ADC portfolio from WuXi Biologics.
• Closing of the $100 million PIPE financing.
• Development of next-generation oncology therapies using the in-licensed ADC assets.

Key Dates

Keywords

Aadi Bioscience, FYARRO, Kaken Pharmaceuticals, Antibody Drug Conjugates, ADC, WuXi Biologics, PIPE Financing, Oncology, Stockholder Vote, Strategic Transactions